HighTower Advisors’s Viking Therapeutics VKTX Stock Holding History

HighTower Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,000	Closed	-$10.2K	–	4077
2025 Q2	$10.2K	Buy	2,000 +1,000	+100%	+$26.3K	﹤0.01%	3645
2025 Q1	$1.54K	Sell	1,000 -2,600	-72%	-$82.2K	﹤0.01%	3636
2024 Q4	$12.3K	Buy	3,600 +3,100	+620%	+$177K	﹤0.01%	3575
2024 Q3	$1.66K	Sell	500 -300	-38%	-$17.6K	﹤0.01%	3645
2024 Q2	$6.24K	Buy	+800	New	+$52.4K	﹤0.01%	3470
2019 Q2	–	Sell	-1,000	Closed	-$2K	–	2519
2019 Q1	$2K	Buy	+1,000	New	+$8.37K	﹤0.01%	2258

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HighTower Advisors's VKTX Position: Q1 2026 in Review

HighTower Advisors sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 7,533 shares — an estimated $265K sold.

HighTower Advisors first reported a position in VKTX in Q3 2018 and held it in 16 quarters. The position peaked at $507K in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

HighTower Advisors reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 7,533 Viking Therapeutics shares in Q1 2026, an estimated $265K.
HighTower Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 16 quarters.
HighTower Advisors's Viking Therapeutics position peaked at $507K in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.